No to drug combinations
the Union ministry of health and family welfare has banned the manufacture and sale of eight drug combinations, as they have no therapeutic value or contain ingredients for which there are no justifications. Manufacturers have to restrict production of these eight combinations so that no stocks are available after December 31, 2001. This decision was taken after the Drugs Technical Advisory Board examined recommendations made by an expert committee instituted by the government to look into all drug combinations. Some top Indian companies such as Wockhardt, Nicholas Piramal, Cipla, Glaxo and Ranbaxy Laboratories have brands that fall in the banned category.
Related Content
- The burden of air pollution in Thailand 2021
- Antimicrobial resistance and water: the risks and costs for economies and societies
- New method for controlled-release makes cancer drugs less toxic to healthy tissues
- IIT-Bombay study gives hope to resistant-TB patients
- Improving diets in an era of food market transformation: Challenges and opportunities for engagement between the public and private sectors
- Researchers combine drug and vaccine to end malaria menace